Does the media prefer TXG or EYPT?

In the previous week, 10x Genomics had 7 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 9 mentions for 10x Genomics and 2 mentions for Eyepoint Pharmaceuticals. 10x Genomics' average media sentiment score of 0.96 beat Eyepoint Pharmaceuticals' score of 0.50 indicating that 10x Genomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eyepoint Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor EYPT or MIR?

In the previous week, Mirion Technologies had 5 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 7 mentions for Mirion Technologies and 2 mentions for Eyepoint Pharmaceuticals. Mirion Technologies' average media sentiment score of 1.19 beat Eyepoint Pharmaceuticals' score of 0.50 indicating that Mirion Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mirion Technologies 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VNT or EYPT?

In the previous week, Vontier had 1 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 3 mentions for Vontier and 2 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.50 beat Vontier's score of 0.41 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vontier 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Eyepoint Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor EYPT or AEHR?

In the previous week, Eyepoint Pharmaceuticals had 1 more articles in the media than Aehr Test Systems. MarketBeat recorded 2 mentions for Eyepoint Pharmaceuticals and 1 mentions for Aehr Test Systems. Eyepoint Pharmaceuticals' average media sentiment score of 0.50 beat Aehr Test Systems' score of 0.33 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aehr Test Systems 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor EYPT or ALMR?

In the previous week, Eyepoint Pharmaceuticals and Eyepoint Pharmaceuticals both had 2 articles in the media. Eyepoint Pharmaceuticals' average media sentiment score of 0.50 beat Alamar Biosciences' score of 0.00 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alamar Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Eyepoint Pharmaceuticals (EYPT) Competitors

$13.98 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$14.02 +0.04 (+0.32%)

As of 07/2/2026 04:38 PM Eastern

Compare

EYPT vs. TXG, MIR, VNT, AEHR, and ALMR

Should you buy Eyepoint Pharmaceuticals stock or one of its competitors? MarketBeat compares Eyepoint Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eyepoint Pharmaceuticals include 10x Genomics (TXG), Mirion Technologies (MIR), Vontier (VNT), Aehr Test Systems (AEHR), and Alamar Biosciences (ALMR). These companies are all part of the "measuring and control equipment" industry.

How does Eyepoint Pharmaceuticals compare to 10x Genomics?

10x Genomics (NASDAQ:TXG) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

10x Genomics currently has a consensus price target of $25.92, indicating a potential downside of 33.56%. Eyepoint Pharmaceuticals has a consensus price target of $43.83, indicating a potential upside of 213.54%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

10x Genomics has a net margin of -3.55% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. 10x Genomics' return on equity of -2.86% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-3.55%	-2.86%	-2.23%
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%

In the previous week, 10x Genomics had 7 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 9 mentions for 10x Genomics and 2 mentions for Eyepoint Pharmaceuticals. 10x Genomics' average media sentiment score of 0.96 beat Eyepoint Pharmaceuticals' score of 0.50 indicating that 10x Genomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 8.8% of 10x Genomics shares are owned by insiders. Comparatively, 5.1% of Eyepoint Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

10x Genomics has higher revenue and earnings than Eyepoint Pharmaceuticals. 10x Genomics is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82M	7.70	-$43.54M	-$0.17	N/A
Eyepoint Pharmaceuticals	$31.37M	37.36	-$231.96M	-$3.50	N/A

10x Genomics has a beta of 2.05, meaning that its share price is 105% more volatile than the broader market. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.73, meaning that its share price is 73% more volatile than the broader market.

Summary

10x Genomics beats Eyepoint Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Mirion Technologies?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Mirion Technologies (NYSE:MIR) are both measuring and control equipment companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

Mirion Technologies has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Mirion Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	37.36	-$231.96M	-$3.50	N/A
Mirion Technologies	$925.40M	4.70	$28.80M	$0.10	173.70

99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. Comparatively, 78.5% of Mirion Technologies shares are held by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are held by company insiders. Comparatively, 6.3% of Mirion Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Mirion Technologies has a net margin of 2.56% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. Mirion Technologies' return on equity of 6.44% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%
Mirion Technologies	2.56%	6.44%	3.48%

In the previous week, Mirion Technologies had 5 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 7 mentions for Mirion Technologies and 2 mentions for Eyepoint Pharmaceuticals. Mirion Technologies' average media sentiment score of 1.19 beat Eyepoint Pharmaceuticals' score of 0.50 indicating that Mirion Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirion Technologies	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eyepoint Pharmaceuticals currently has a consensus target price of $43.83, suggesting a potential upside of 213.54%. Mirion Technologies has a consensus target price of $27.13, suggesting a potential upside of 56.16%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Mirion Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
Mirion Technologies	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Eyepoint Pharmaceuticals has a beta of 1.73, suggesting that its share price is 73% more volatile than the broader market. Comparatively, Mirion Technologies has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

Summary

Mirion Technologies beats Eyepoint Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Vontier?

Vontier (NYSE:VNT) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both measuring and control equipment companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

In the previous week, Vontier had 1 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 3 mentions for Vontier and 2 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.50 beat Vontier's score of 0.41 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vontier	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vontier has a net margin of 13.37% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. Vontier's return on equity of 37.88% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vontier	13.37%	37.88%	10.90%
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%

95.8% of Vontier shares are owned by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 1.1% of Vontier shares are owned by insiders. Comparatively, 5.1% of Eyepoint Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Vontier has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Vontier, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vontier	$3.08B	1.31	$406.10M	$2.83	10.11
Eyepoint Pharmaceuticals	$31.37M	37.36	-$231.96M	-$3.50	N/A

Vontier has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.73, indicating that its share price is 73% more volatile than the broader market.

Vontier currently has a consensus price target of $42.38, indicating a potential upside of 48.15%. Eyepoint Pharmaceuticals has a consensus price target of $43.83, indicating a potential upside of 213.54%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Vontier.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vontier	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Vontier and Eyepoint Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Aehr Test Systems?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Aehr Test Systems (NASDAQ:AEHR) are both measuring and control equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

In the previous week, Eyepoint Pharmaceuticals had 1 more articles in the media than Aehr Test Systems. MarketBeat recorded 2 mentions for Eyepoint Pharmaceuticals and 1 mentions for Aehr Test Systems. Eyepoint Pharmaceuticals' average media sentiment score of 0.50 beat Aehr Test Systems' score of 0.33 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aehr Test Systems	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aehr Test Systems has a net margin of -25.23% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. Aehr Test Systems' return on equity of -7.15% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%
Aehr Test Systems	-25.23%	-7.15%	-6.15%

Aehr Test Systems has higher revenue and earnings than Eyepoint Pharmaceuticals. Aehr Test Systems is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	37.36	-$231.96M	-$3.50	N/A
Aehr Test Systems	$58.97M	37.31	-$3.91M	-$0.38	N/A

Eyepoint Pharmaceuticals currently has a consensus target price of $43.83, suggesting a potential upside of 213.54%. Aehr Test Systems has a consensus target price of $68.00, suggesting a potential downside of 2.80%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Aehr Test Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
Aehr Test Systems	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.7% of Aehr Test Systems shares are owned by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are owned by company insiders. Comparatively, 6.8% of Aehr Test Systems shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Eyepoint Pharmaceuticals has a beta of 1.73, meaning that its share price is 73% more volatile than the broader market. Comparatively, Aehr Test Systems has a beta of 3.17, meaning that its share price is 217% more volatile than the broader market.

Summary

Eyepoint Pharmaceuticals beats Aehr Test Systems on 9 of the 17 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Alamar Biosciences?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Alamar Biosciences (NASDAQ:ALMR) are both small-cap measuring and control equipment companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Alamar Biosciences has higher revenue and earnings than Eyepoint Pharmaceuticals. Alamar Biosciences is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	37.36	-$231.96M	-$3.50	N/A
Alamar Biosciences	$87.16M	20.63	-$120.60M	-$1.74	N/A

In the previous week, Eyepoint Pharmaceuticals and Eyepoint Pharmaceuticals both had 2 articles in the media. Eyepoint Pharmaceuticals' average media sentiment score of 0.50 beat Alamar Biosciences' score of 0.00 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alamar Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alamar Biosciences has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. Alamar Biosciences' return on equity of 0.00% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%
Alamar Biosciences	N/A	N/A	N/A

99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Eyepoint Pharmaceuticals currently has a consensus target price of $43.83, indicating a potential upside of 213.54%. Alamar Biosciences has a consensus target price of $30.00, indicating a potential upside of 15.65%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Alamar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.00
Alamar Biosciences	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Eyepoint Pharmaceuticals beats Alamar Biosciences on 9 of the 15 factors compared between the two stocks.

Get Eyepoint Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EYPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EYPT vs. The Competition

Export

Metric	Eyepoint Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.17B	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-3.99	21.61	28.02	24.70
Price / Sales	37.36	340.19	540.37	99.46
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	3.78	8.66	10.96	6.46
Net Income	-$231.96M	$23.81M	$3.57B	$337.01M
7 Day Performance	2.34%	3.39%	2.12%	1.69%
1 Month Performance	18.68%	10.81%	5.25%	3.81%
1 Year Performance	42.16%	62.61%	33.29%	23.90%

Eyepoint Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EYPT Eyepoint Pharmaceuticals	3.1294 of 5 stars	$13.98 flat	$43.83 +213.5%	+42.2%	$1.17B	$31.37M	N/A	120	Analyst Forecast
TXG 10x Genomics	1.7955 of 5 stars	$37.76 +1.6%	$24.00 -36.4%	+199.8%	$4.80B	$638.78M	N/A	1,240	Analyst Forecast
MIR Mirion Technologies	4.3356 of 5 stars	$17.86 +2.3%	$27.13 +51.9%	-14.6%	$4.47B	$981M	178.60	3,281	Positive News Gap Up
VNT Vontier	4.1056 of 5 stars	$28.91 +0.7%	$42.38 +46.6%	-25.6%	$4.07B	$3.08B	10.21	7,800
AEHR Aehr Test Systems	1.5161 of 5 stars	$96.42 +1.7%	$68.00 -29.5%	+351.1%	$3.04B	$58.97M	N/A	90	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EYPT) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eyepoint Pharmaceuticals (EYPT) Competitors

EYPT vs. TXG, MIR, VNT, AEHR, and ALMR

How does Eyepoint Pharmaceuticals compare to 10x Genomics?

Summary

How does Eyepoint Pharmaceuticals compare to Mirion Technologies?

Summary

How does Eyepoint Pharmaceuticals compare to Vontier?

Summary

How does Eyepoint Pharmaceuticals compare to Aehr Test Systems?

Summary

How does Eyepoint Pharmaceuticals compare to Alamar Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EYPT vs. The Competition

Eyepoint Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eyepoint Pharmaceuticals (EYPT) Competitors

EYPT vs. TXG, MIR, VNT, AEHR, and ALMR

How does Eyepoint Pharmaceuticals compare to 10x Genomics?

Do analysts prefer TXG or EYPT?

Is TXG or EYPT more profitable?

Does the media prefer TXG or EYPT?

Do institutionals and insiders have more ownership in TXG or EYPT?

Which has preferable valuation and earnings, TXG or EYPT?

Which has more risk & volatility, TXG or EYPT?

Summary

How does Eyepoint Pharmaceuticals compare to Mirion Technologies?

Which has better earnings and valuation, EYPT or MIR?

Do institutionals & insiders have more ownership in EYPT or MIR?

Is EYPT or MIR more profitable?

Does the media favor EYPT or MIR?

Do analysts recommend EYPT or MIR?

Which has more volatility and risk, EYPT or MIR?

Summary

How does Eyepoint Pharmaceuticals compare to Vontier?

Does the media prefer VNT or EYPT?

Is VNT or EYPT more profitable?

Do institutionals and insiders believe in VNT or EYPT?

Which has stronger valuation and earnings, VNT or EYPT?

Which has more volatility & risk, VNT or EYPT?

Do analysts recommend VNT or EYPT?

Summary

How does Eyepoint Pharmaceuticals compare to Aehr Test Systems?

Does the media favor EYPT or AEHR?

Is EYPT or AEHR more profitable?

Which has higher earnings and valuation, EYPT or AEHR?

Do analysts rate EYPT or AEHR?

Do insiders and institutionals have more ownership in EYPT or AEHR?

Which has more risk & volatility, EYPT or AEHR?

Summary

How does Eyepoint Pharmaceuticals compare to Alamar Biosciences?

Which has stronger earnings and valuation, EYPT or ALMR?

Does the media favor EYPT or ALMR?

Is EYPT or ALMR more profitable?

Do insiders & institutionals hold more shares of EYPT or ALMR?

Do analysts rate EYPT or ALMR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EYPT vs. The Competition

Eyepoint Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools